Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.01 -0.65 (-1.60%)
Official Closing Price Updated: 7:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga 
Via TheNewswire.com
Exposures Product Safety
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
Exposures Product Safety
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
MarketBeat Week in Review – 3/13 - 3/17
The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
From Pfizer Inc.
Via Business Wire
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Pfizer Invests $43 Billion to Battle Cancer
From Seagen Inc.
Via Business Wire
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
From Pfizer Inc.
Via Business Wire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Lucy Scientific Discovery, Inc. Scores Major Milestone, Transitions To Revenue Generating Company With First Commercial Sale Of Psilocybin ($LSDI)
Via AB Newswire
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its 
Via MarketBeat
Topics Initial Public Offering
Exposures COVID-19 Product Safety Securities Market
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Dr. Harte asks: “‘Public Health?’ THE serious hazard to health?”
Corte Madera, California, United States - 02-22-2023 (PR Distribution™) - 
Via PR Distribution
Exposures COVID-19
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
From Pfizer Inc.
Via Business Wire
What Are Dividend Payment Dates?
What are dividend payment dates? The payment date is the day a company pays its eligible shareholders dividends. Learn more. 
Via MarketBeat
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
From Pfizer Inc.
Via Business Wire
Bladder Prolapse (Cystocele) Market to Touch at High CAGR of 8.3% by 2022-2029
Bladder Prolapse (cystocele) Market is expected to grow at a CAGR of 8.3 % during the forecast period (2022-2029). 
Via SBWire
Salivary Gland Cancer Treatment Market Outlook Growth Share Overview Analysis 2022-2029
Global Salivary Gland Cancer Treatment Market to Witness Huge Growth by Key Players: Bristol-Myers Squibb Company, LGM PHARMA, Pfizer Inc., Bedford Laboratories, Baxter, sanofi-aventis U.S. LLC, Pierre... 
Via SBWire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer... 
Via SBWire
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029). 
Via SBWire
Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead
Animal health company Zoetis is up 7.99% in the past week, after topping fourth-quarter views. Analysts see double-digit EPS growth in 2023 and 2024. 
Via MarketBeat
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
From Pfizer Inc.
Via Business Wire
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
From Pfizer Inc.
Via Business Wire
Ziprasidone Market Trends Share Demand Overview Analysis 2022-2029
Global Ziprasidone Market to Witness Huge Growth by Key Players: Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Apotex, Dr. Reddy's laboratories Ltd., Wockhardt, Aurobindo... 
Via SBWire
Spinal Stenosis Treatment Market to Grow with a Growth Rate of 4% During 2022 to 2029
Spinal Stenosis Treatment Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 4% during the forecast period (2022-2029). 
Via SBWire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.